Advertisement
Advertisement
HROW
Harrow, Inc. Common Stock
40.44
USDSponsored
+0.52
+1.30%
Aug 07, 15:59 UTC -4
Closed
After-Market
40.45
+0.01
+0.01%
HROW Earnings Reports
Positive Surprise Ratio
HROW beat 12 of 34 last estimates.
35%
Next Report
Tomorrow AMC
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$71.75M
/-$0.18
Implied change from Q1 26 (Revenue/ EPS)
+62.32%
/-75.68%
Implied change from Q2 25 (Revenue/ EPS)
+12.56%
/-238.46%
Harrow, Inc. Common Stock earnings per share and revenue
On May 11, 2026, HROW reported earnings of -0.74 USD per share (EPS) for Q1 26, missing the estimate of -0.40 USD, resulting in a -80.71% surprise. Revenue reached 44.20 million, compared to an expected 53.47 million, with a -17.33% difference. The market reacted with a -23.69% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 8 analysts forecast an EPS of -0.18 USD, with revenue projected to reach 71.75 million USD, implying an decrease of -75.68% EPS, and increase of 62.32% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.36
Actual
$0.31
Surprise
-14.62%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
Avita Medical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.25
Surprise
+14.50%
electroCore, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.33
Surprise
+23.40%
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.36
Actual
-$0.39
Surprise
-5.95%
FAQ
What were Harrow, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Harrow, Inc. Common Stock reported EPS of -$0.74, missing estimates by -80.71%, and revenue of $44.20M, -17.33% below expectations.
How did the market react to Harrow, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -23.69%, changed from $38.04 before the earnings release to $29.03 the day after.
When is Harrow, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Harrow, Inc. Common Stock's next earnings report?
Based on 8
analysts, Harrow, Inc. Common Stock is expected to report EPS of -$0.18 and revenue of $71.75M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement